Immune checkpoint inhibitors (ICIs) has opened a new chapter in the treatment of liver cancer and has become one of the main options for liver cancer transformation and adjuvant therapy. At present, ICIs has been widely used in the down-staging treatment of liver cancer before liver transplantation, and some exploratory applications have also been made in the treatment of liver cancer recurrence and metastasis after liver transplantation. However, due to the potential risk of rejection reactions induced by ICIs, there are still many doubts and problems in the application of ICIs before and after liver transplantation for liver cancer. In this paper, research reports related to this field domestic and overseas in recent years are comprehensively analyzed, aiming at providing references for the reasonable, safe and effective application of ICIs before and after liver transplantation.   

无